[go: up one dir, main page]

UA105556C2 - Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами - Google Patents

Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами

Info

Publication number
UA105556C2
UA105556C2 UAA201209253A UAA201209253A UA105556C2 UA 105556 C2 UA105556 C2 UA 105556C2 UA A201209253 A UAA201209253 A UA A201209253A UA A201209253 A UAA201209253 A UA A201209253A UA 105556 C2 UA105556 C2 UA 105556C2
Authority
UA
Ukraine
Prior art keywords
compounds
combination
integrase inhibitors
hiv integrase
therapeutical agents
Prior art date
Application number
UAA201209253A
Other languages
English (en)
Russian (ru)
Inventor
Марк Річард Ундервуд
Original Assignee
Віів Гелскер Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA105556(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Віів Гелскер Компані filed Critical Віів Гелскер Компані
Publication of UA105556C2 publication Critical patent/UA105556C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Даний винахід належить до комбінацій сполук, що містять інгібітори ВІЛ інтегрази та інші терапевтичні агенти. Такі комбінації корисні в інгібуванні ВІЛ реплікації, профілактиці та/або лікуванні ВІЛ інфікування і при лікуванні СНІД та/або ARC.
UAA201209253A 2010-01-27 2011-01-24 Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами UA105556C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
PCT/US2011/022219 WO2011094150A1 (en) 2010-01-27 2011-01-24 Antiviral therapy

Publications (1)

Publication Number Publication Date
UA105556C2 true UA105556C2 (uk) 2014-05-26

Family

ID=44319704

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201209253A UA105556C2 (uk) 2010-01-27 2011-01-24 Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами

Country Status (45)

Country Link
US (13) US20120295898A1 (uk)
EP (6) EP4316599A3 (uk)
JP (8) JP2013518107A (uk)
KR (4) KR20170078868A (uk)
CN (2) CN105311033B (uk)
AP (1) AP3551A (uk)
AU (1) AU2011209788C1 (uk)
BR (1) BR112012018670A2 (uk)
CA (4) CA2967453C (uk)
CL (1) CL2012002080A1 (uk)
CO (1) CO6602152A2 (uk)
CR (1) CR20120423A (uk)
CY (4) CY1116509T1 (uk)
DK (4) DK3494972T3 (uk)
DO (2) DOP2012000205A (uk)
EA (4) EA202190473A3 (uk)
EC (1) ECSP12012106A (uk)
ES (4) ES2670811T3 (uk)
FI (2) FI3494972T3 (uk)
FR (2) FR18C1043I2 (uk)
HK (3) HK1250335A1 (uk)
HR (4) HRP20240168T1 (uk)
HU (6) HUE040554T2 (uk)
IL (5) IL221007A (uk)
LT (4) LT3127542T (uk)
LU (1) LUC00090I2 (uk)
MA (1) MA34002B1 (uk)
ME (2) ME03058B (uk)
MX (4) MX367937B (uk)
MY (2) MY188334A (uk)
NO (2) NO2932970T3 (uk)
NZ (4) NZ627827A (uk)
PE (2) PE20160180A1 (uk)
PH (3) PH12012501537A1 (uk)
PL (4) PL2932970T3 (uk)
PT (4) PT3127542T (uk)
RS (4) RS57728B1 (uk)
SG (3) SG10201707183TA (uk)
SI (4) SI3127542T1 (uk)
SM (4) SMT201800290T1 (uk)
TN (1) TN2012000376A1 (uk)
TR (1) TR201807704T4 (uk)
UA (1) UA105556C2 (uk)
WO (1) WO2011094150A1 (uk)
ZA (1) ZA201205586B (uk)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57728B1 (sr) 2010-01-27 2018-12-31 Viiv Healthcare Co Antivirusna terapija
AU2013336491B2 (en) 2012-10-23 2018-08-02 Cipla Limited Pharmaceutical antiretroviral composition
SG11201504857SA (en) 2012-12-21 2015-07-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
US9480655B2 (en) 2013-02-18 2016-11-01 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
NO2865735T3 (uk) 2013-07-12 2018-07-21
LT3019503T (lt) 2013-07-12 2017-11-27 Gilead Sciences, Inc. Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui
EP3049081B1 (en) 2013-09-27 2019-11-27 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
WO2015187998A2 (en) 2014-06-04 2015-12-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (uk) 2014-06-20 2018-06-23
WO2016016279A1 (en) 2014-07-29 2016-02-04 Lek Pharmaceuticals D.D. Novel hydrates of dolutegravir sodium
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
TR201905009T4 (tr) 2015-04-02 2019-05-21 Gilead Sciences Inc Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
WO2017029226A1 (en) 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
KR20200031658A (ko) 2017-07-21 2020-03-24 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법
US20200147092A1 (en) * 2017-07-21 2020-05-14 Viiv Healthcare Company Regimens for treating hiv infections and aids
KR20200070246A (ko) * 2017-10-13 2020-06-17 비이브 헬쓰케어 컴퍼니 이중층 제약 정제 제제
PH12021500040A1 (en) 2019-03-22 2022-06-06 Gilead Sciences Inc Bridged tricyclic carbamolypyridone compunds and their pharmaceutical use
CN114901363A (zh) * 2020-01-09 2022-08-12 华盛顿大学 长效治疗剂组合物及其方法
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
HUE064467T2 (hu) 2021-01-19 2024-03-28 Gilead Sciences Inc Szubsztituált piridotriazin-származékok és alkalmazásuk
AU2023225805A1 (en) * 2022-02-28 2024-10-17 Jericho Sciences, Llc Methods for viral infections
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
EP0938321B1 (en) * 1996-06-25 2004-01-14 Glaxo Group Limited Combinations comprising vx478, zidovudine and 3tc for use in the treatment of hiv
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
WO1999048371A1 (en) 1998-03-27 1999-09-30 The Regents Of The University Of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
PL211860B1 (pl) 2000-01-31 2012-07-31 Cook Biotech Inc Zespół zastawki stentu
EE05400B1 (et) 2001-04-10 2011-04-15 Pfizer Inc. Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
BR0311141A (pt) 2002-06-27 2005-06-07 Medivir Ab Interação sinergìstica de abacavir e alovudine
EP3025718A1 (en) * 2003-01-14 2016-06-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CA2555176A1 (en) * 2004-02-11 2005-08-25 Smithkline Beecham Corporation Hiv integrase inhibitors
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
ATE411030T1 (de) * 2004-04-14 2008-10-15 Gilead Sciences Inc Phosphonatanaloga von hiv- integrasehemmerverbindungen
EP2229945A1 (en) * 2004-05-21 2010-09-22 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
JP4559431B2 (ja) 2004-08-23 2010-10-06 テバ ファーマシューティカル インダストリーズ リミティド 固体及び結晶イバンドロネートナトリウム及びその調製方法
KR101284361B1 (ko) 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
WO2006054182A2 (en) 2004-09-16 2006-05-26 Idenix Pharmaceuticals, Inc. Phosphoindoles as hiv inhibitors
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
EP1853604A4 (en) 2005-03-04 2010-02-24 Smithkline Beecham Corp CHEMICAL COMPOUNDS
CN101212903B (zh) * 2005-04-28 2013-07-24 史密丝克莱恩比彻姆公司 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
BRPI0610030B8 (pt) * 2005-04-28 2022-01-11 Glaxosmithkline Llc Composto, composição farmacêutica, e, uso de um composto
CA2610029A1 (en) 2005-06-01 2006-12-07 Bioalliance Pharma Synergic combinations comprising a quinoline compound and other hiv infection therapeutic agents
CA2635468C (en) * 2005-12-30 2016-08-09 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
UA101141C2 (uk) * 2005-12-30 2013-03-11 Гилиад Сайенсиз, Инк. Спосіб покращення фармакокінетики інгібіторів інтегрази віл
KR101501475B1 (ko) * 2006-01-20 2015-03-19 얀센 알 앤드 디 아일랜드 Ｔｍｃ２７８을 이용한 ｈｉｖ 감염의 장기간 요법
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
NZ573887A (en) 2006-07-21 2012-02-24 Gilead Sciences Inc Antiviral protease inhibitors
CA2664396A1 (en) 2006-09-29 2008-04-10 Idenix Pharmaceuticals, Inc. Enantiomerically pure phosphoindoles as hiv inhibitors
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science Inc Moduladores de propriedades farmacocinéticas de produtos terapêuticos
TW200835693A (en) 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
TW200918507A (en) 2007-06-29 2009-05-01 Gilead Sciences Inc Novel HIV reverse transcriptase inhibitors
WO2009005693A1 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Novel hiv reverse transcriptase inhibitors
KR20100040896A (ko) 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
US8426434B2 (en) * 2007-07-12 2013-04-23 Tibotec Pharmaceuticals Ltd. Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
US8466177B2 (en) 2007-11-01 2013-06-18 The Uab Research Foundation Treating and preventing viral infections
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
CA2711420A1 (en) 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
WO2009082819A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
EP2231628B1 (en) 2008-01-04 2015-10-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
EP2257567A1 (en) 2008-02-14 2010-12-08 Virochem Pharma Inc. Novel 17 beta lupane derivatives
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
ES2448766T3 (es) * 2008-07-25 2014-03-17 Viiv Healthcare Company Profármacos de dolutegravir
MX351942B (es) * 2008-12-11 2017-11-03 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
CN104788367A (zh) 2008-12-11 2015-07-22 盐野义制药株式会社 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
RS57728B1 (sr) 2010-01-27 2018-12-31 Viiv Healthcare Co Antivirusna terapija
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
US8933075B2 (en) 2010-06-17 2015-01-13 Fuzians Biomedicals, Inc. Compounds useful as antiviral agents, compositions, and methods of use
RU2623039C2 (ru) 2011-04-01 2017-06-21 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта

Also Published As

Publication number Publication date
LT3127542T (lt) 2018-11-26
US20170079982A1 (en) 2017-03-23
US20180200254A1 (en) 2018-07-19
LT3494972T (lt) 2024-03-12
DK3127542T3 (en) 2018-11-12
DK2531027T3 (en) 2015-07-20
CY1120457T1 (el) 2019-07-10
SMT202400063T1 (it) 2024-03-13
DK2932970T3 (en) 2018-05-28
IL281959A (en) 2021-05-31
HUE026849T2 (en) 2016-08-29
PH12012501537A1 (en) 2018-02-07
FI3494972T3 (fi) 2024-03-01
MA34002B1 (fr) 2013-02-01
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
PL3494972T3 (pl) 2024-05-27
JP2021091705A (ja) 2021-06-17
KR101830715B1 (ko) 2018-04-04
NO2932970T3 (uk) 2018-08-18
FR18C1043I1 (uk) 2018-11-30
SI2531027T1 (sl) 2015-08-31
MX356891B (es) 2018-06-19
IL257267A (en) 2018-03-29
SMT201800594T1 (it) 2019-01-11
HK1209629A1 (en) 2016-04-08
BR112012018670A2 (pt) 2018-02-06
EA037601B1 (ru) 2021-04-20
CN105311033B (zh) 2019-05-07
IL245182B (en) 2018-04-30
CA2787691C (en) 2018-07-17
EA201690872A2 (ru) 2016-08-31
AP3551A (en) 2016-01-18
WO2011094150A1 (en) 2011-08-04
EP3127542A1 (en) 2017-02-08
HUS2400017I1 (hu) 2024-06-28
US20250017939A1 (en) 2025-01-16
LT2932970T (lt) 2018-06-25
HK1250335A1 (zh) 2018-12-14
SI3127542T1 (sl) 2018-11-30
EP2932970A1 (en) 2015-10-21
CA3060290A1 (en) 2011-08-04
PT3494972T (pt) 2024-02-12
RS65183B1 (sr) 2024-03-29
KR20170078868A (ko) 2017-07-07
PL3127542T3 (pl) 2019-03-29
EP3494972B1 (en) 2023-12-13
EA025176B1 (ru) 2016-11-30
DOP2021000147A (es) 2022-01-16
CA3003988C (en) 2020-01-07
EP3127542B1 (en) 2018-08-22
PT2531027E (pt) 2015-09-16
RS57728B1 (sr) 2018-12-31
US20160199379A1 (en) 2016-07-14
JP2018127473A (ja) 2018-08-16
SMT201800290T1 (it) 2018-07-17
PL2531027T3 (pl) 2016-01-29
JP2019167371A (ja) 2019-10-03
ME02182B (me) 2015-10-20
US20170216284A1 (en) 2017-08-03
JP2022071126A (ja) 2022-05-13
MX367938B (es) 2019-09-12
AU2011209788B2 (en) 2014-02-06
US20200230147A1 (en) 2020-07-23
EP3351249A1 (en) 2018-07-25
CA3003988A1 (en) 2011-08-04
KR20180078358A (ko) 2018-07-09
US20180098992A1 (en) 2018-04-12
CO6602152A2 (es) 2013-01-18
MY202778A (en) 2024-05-21
CN102791129A (zh) 2012-11-21
KR101964923B1 (ko) 2019-04-02
EP3494972A1 (en) 2019-06-12
CY1121040T1 (el) 2019-12-11
US20210401850A1 (en) 2021-12-30
PH12016500195B1 (en) 2021-08-04
HK1179522A1 (en) 2013-10-04
HRP20181531T1 (hr) 2018-11-16
SI3494972T1 (sl) 2024-03-29
HUE065569T2 (hu) 2024-06-28
HUS1800042I1 (hu) 2018-11-28
CN102791129B (zh) 2015-09-30
PE20121524A1 (es) 2012-12-03
ME03058B (me) 2019-01-20
IL221007A0 (en) 2012-09-24
MX2012008774A (es) 2012-08-17
FR18C1043I2 (fr) 2019-10-11
ECSP12012106A (es) 2013-05-31
AU2011209788A1 (en) 2012-08-16
CY1116509T1 (el) 2017-03-15
IL267658A (en) 2019-08-29
US20120295898A1 (en) 2012-11-22
CR20120423A (es) 2012-11-22
EP2531027B1 (en) 2015-05-06
SMT201500177B (it) 2015-09-07
EP2932970B1 (en) 2018-03-21
EP2531027A1 (en) 2012-12-12
JP6268386B2 (ja) 2018-01-31
HRP20150770T1 (hr) 2015-08-28
CY2018029I2 (el) 2019-07-10
PL2932970T3 (pl) 2018-08-31
LUC00090I2 (uk) 2019-01-08
US20150238496A1 (en) 2015-08-27
TN2012000376A1 (en) 2014-01-30
EP4316599A2 (en) 2024-02-07
CA3060290C (en) 2022-07-12
CA2967453A1 (en) 2011-08-04
US10426780B2 (en) 2019-10-01
CA2787691A1 (en) 2011-08-04
US20170119777A1 (en) 2017-05-04
CL2012002080A1 (es) 2012-11-30
IL281959B (en) 2021-12-01
LTC2932970I2 (lt) 2022-04-25
EA201690872A3 (ru) 2016-12-30
CN105311033A (zh) 2016-02-10
NO2018036I1 (no) 2018-10-15
DOP2012000205A (es) 2012-10-15
MX367937B (es) 2019-09-12
TR201807704T4 (tr) 2018-06-21
NZ627824A (en) 2016-02-26
EA202190473A2 (ru) 2021-06-30
LTPA2018013I1 (lt) 2018-11-12
PH12018502489A1 (en) 2020-06-15
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
KR101883750B1 (ko) 2018-07-31
EA202190473A3 (ru) 2021-12-31
IL245182A0 (en) 2016-06-30
EA201892277A1 (ru) 2019-03-29
SG10201509476RA (en) 2015-12-30
EA032868B1 (ru) 2019-07-31
ES2688925T3 (es) 2018-11-07
KR20160111536A (ko) 2016-09-26
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
KR20120128640A (ko) 2012-11-27
NZ601319A (en) 2014-08-29
HRP20180855T1 (hr) 2018-06-29
US11234985B2 (en) 2022-02-01
PH12016500195A1 (en) 2016-12-05
SI2932970T1 (en) 2018-07-31
NZ627826A (en) 2016-01-29
SG10201707183TA (en) 2017-10-30
JP2023085431A (ja) 2023-06-20
HUE037812T2 (hu) 2018-09-28
DK3494972T3 (da) 2024-01-29
AP2012006445A0 (en) 2012-08-31
IL267658B (en) 2021-04-29
CY2018029I1 (el) 2019-07-10
EP4316599A3 (en) 2024-04-10
JP2013518107A (ja) 2013-05-20
MY188334A (en) 2021-11-30
EP2531027A4 (en) 2013-07-03
PT2932970T (pt) 2018-06-08
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
US20160339033A1 (en) 2016-11-24
NZ627827A (en) 2016-02-26
ES2969969T3 (es) 2024-05-23
ES2670811T3 (es) 2018-06-01
CA2967453C (en) 2018-07-17
PT3127542T (pt) 2018-11-26
HUE040554T2 (hu) 2019-03-28
AU2011209788C1 (en) 2014-08-28
JP2017008087A (ja) 2017-01-12
JP2016145204A (ja) 2016-08-12
FIC20240016I1 (fi) 2024-05-31
RS54123B1 (en) 2015-12-31
EA201290583A1 (ru) 2013-04-30
US20170281636A1 (en) 2017-10-05
ES2543066T3 (es) 2015-08-14

Similar Documents

Publication Publication Date Title
PH12018502489A1 (en) Antiviral therapy
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
PH12015502056A1 (en) Benzothiazole compounds and their pharmaceutical use
IN2015DN01156A (uk)
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
MD4754B1 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
IN2012DN00971A (uk)
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MX343505B (es) Metodos y composiciones para inhibir la transmision del vih.
TW200738700A (en) HIV integrase inhibitors
PH12013500559A1 (en) Combination therapy for treating hcv infection
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
MX364704B (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
WO2010111718A3 (en) Antiviral compounds and methods of use thereof
TN2013000134A1 (en) Combination therapy for treating hcv infection